A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer

Inclusion Criteria:

* Newly diagnosed stage IIIA/ IIIB squamous cell lung cancer;
* All sites of disease must be amenable to definitive radiotherapy;
* Age 18 years to 75 years;
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2;
* Forced expiratory volume in 1 second(FEV1)\> 0.75L;
* No previous chest radiotherapy, immunotherapy or biotherapy;
* Adequate bone marrow, liver and renal function, as specified below: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100 x 109/L; Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) ; Aspartate transaminase(AST) and alanine Transaminase(ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present; Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
* For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
* Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter;
* Patients and their family signed the informed consents;

Exclusion Criteria:

* Active infection;
* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias);
* Malnutrition (loss of ≥ 20% of the original body weight);
* Performance status: 3-4;
* Sensor or motor neuropathy \> grade I;
* Second primary malignancy, except for non-melanoma skin cancer;
* Psychiatric illness or social situation that would preclude study compliance;
* Pregnant or lactating women.